Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3134298 | International Journal of Oral and Maxillofacial Surgery | 2006 | 5 Pages |
The successful therapeutic use of calcitonin in patients with a central giant cell granuloma has been shown in several case reports. In a prospective, randomized, double-blinded, placebo-controlled clinical trial, 14 patients with a histologically confirmed central giant cell granuloma and normal calcium and parathyroid hormone serum levels were studied over 2 years. Patients were treated with intranasally administered salmon calcitonin (200 IU/day) or a placebo once a day. The placebo-controlled period was 3 months, after which all patients were treated with calcitonin for 1 year. Treatment response was assessed at the end of the placebo-controlled study phase (3 months), at the end of therapy (15 months’ timepoint with patients being on calcitonin treatment for either 12 or 15 months) and at 6 months’ follow-up. The χ2-test was used to compare the proportion of patients with a tumour reduction ≥10% of the pretreatment measurement between the 2 populations at the 3 timepoints: no differences were observed between the placebo group and the calcitonin group. At the 6-month follow-up timepoint, tumour volume had decreased by ≥10% in a total of 7 patients with a 37.9% (95% CI 31.3–44.5%) mean volume reduction in this subgroup. Complete remission was not observed.